Oxymetazoline and Budesonide Produced a Clear Symptom Advantage in Chronic Nasal Obstruction
A randomized clinical trial in adults with chronic nasal obstruction found that a combination spray containing oxymetazoline and budesonide produced substantially better symptom relief than budesonide alone, without rebound obstruction during the study window. The finding is clinically consequential because oxymetazoline has long been viewed as a drug that works quickly but cannot be trusted for ongoing use; prolonged exposure is associated with rhinitis medicamentosa, the pattern of worsening congestion that follows decongestant overuse. In this trial, the paired strategy appeared to preserve the vasoconstrictor benefit while avoiding the familiar rebound trap over several weeks of treatment and tapering.
The biologic logic is straightforward. Oxymetazoline reduces nasal mucosal edema through potent alpha-adrenergic vasoconstriction, while budesonide suppresses the inflammatory drive that keeps the mucosa swollen in chronic rhinitis. If inflammation is dampened enough, the decongestant may no longer need to fight against a constantly engorged nasal cavity, which may explain why the combination outperformed steroid monotherapy in patients who had already failed topical steroids.
Trial Design Focused on Refractory Nasal Congestion
The study was a single-center, double-blind, randomized clinical trial conducted at Washington University in St Louis/Barnes Jewish Hospital from October 2024 to July 2025. Adults with chronic nasal obstruction were eligible if they had already failed topical steroids and did not have chronic sinusitis. That population matters. These were not first-line patients with transient congestion; they were individuals with persistent symptoms despite the therapy most clinicians would normally expect to help.
After screening 87 individuals, 61 signed informed consent and 60 completed baseline assessments and randomization. Thirty-one participants received the combination spray and 29 received budesonide alone. The mean age was 46.0 years in the combination group and 51.2 years in the budesonide group. Women made up 58.1% of the combination arm and 58.6% of the control arm. The demographic balance between groups supports the internal comparison, even in a modestly sized trial.
Treatment was delivered twice daily for 4 weeks, followed by a 3-week wean period. The investigators also incorporated a histopathologic component: 10 participants underwent inferior turbinate biopsies before and after treatment to assess tissue change. That tissue-level work is important because rhinitis medicamentosa is not just a symptom pattern; it is also a mucosal phenomenon marked by structural and inflammatory changes that may become visible under the microscope if decongestant exposure is harmful.
Responder Rates Favored the Combination by a Wide Margin
The primary endpoint was the proportion of responders, defined as at least moderate improvement on the Clinical Global Impressions-Improvement scale after 4 weeks. Here the difference was large. Twenty-four of 29 participants in the oxymetazoline-budesonide arm responded, compared with 10 of 28 in the budesonide-only arm. The absolute difference was 47 percentage points, with a 95% confidence interval of 25 to 70 percentage points.
That degree of separation is difficult to ignore in a symptomatic airway disorder where patients often judge success by whether they can breathe through the nose, sleep more comfortably, or function without constant congestion. The magnitude of benefit suggests that for selected patients, the vasoconstrictor component did not merely add convenience; it changed the clinical response profile in a meaningful way.
One sentence captures the central result plainly: the combination arm produced far more responders than budesonide alone.
No Signal of Rebound Obstruction Emerged During Active Treatment or Weaning
The safety question is the one clinicians will ask first, and it was answered cautiously but reassuringly within the study limits. None of the participants in the oxymetazoline arm developed worsening obstruction concerning for rebound during active treatment. All successfully weaned off oxymetazoline without issue.
This matters because the classic concern with topical decongestants is not only transient benefit, but dependence on a medication that can worsen the problem it was meant to solve. Rhinitis medicamentosa can turn a quick fix into a chronic cycle of congestion and escalating spray use. In this trial, the combination strategy did not produce that pattern over the treatment and taper period that was studied.
A second concise fact stands out: every participant in the oxymetazoline group was able to stop the drug successfully.
The absence of observed rebound should not be overread as proof that the risk has disappeared. The trial was short, single-center, and designed around a limited follow-up window. Longer exposure could behave differently, and a study of this size cannot exclude less common adverse outcomes that would emerge only with broader use.
Tissue Sampling Added Biological Context, but the Dataset Was Small
The inferior turbinate biopsy component adds a useful mechanistic layer, even though only 10 participants underwent histopathologic analysis. In chronic rhinitis, nasal obstruction reflects more than mucosal swelling alone; vascular tone, inflammatory infiltrates, and epithelial changes all influence airflow resistance. A treatment that combines an anti-inflammatory steroid with a vasoconstrictor is biologically plausible because it addresses both sides of that equation at once.
Still, the biopsy sample is too small to support broad claims about tissue remodeling or to define which histologic patterns predict response. The clinical result is stronger than the tissue dataset, and the tissue dataset should be viewed as supportive rather than definitive.
What the Trial Means for Patients Who Have Failed Steroid Sprays
For patients with chronic nasal obstruction who have not improved on topical steroids, this trial opens the door to a more aggressive intranasal strategy. The combination of oxymetazoline and budesonide may be considered in carefully selected patients, especially when congestion remains severe and quality of life is impaired. The study suggests that clinicians do not necessarily have to choose between symptom control and the fear of immediate rebound, at least over the short course tested here.
The result also raises a practical bedside question: whether short-term oxymetazoline exposure, buffered by concurrent budesonide, can be used as a controlled bridge rather than an unmonitored crutch. The answer from this trial is encouraging, but not final. Chronic rhinitis is heterogeneous, and response in one single-center cohort may not mirror response in broader outpatient practice.
Several boundaries remain in place. Follow-up was limited. The trial was conducted at a single center. Only 10 participants had biopsy data. And although the study found no signs or symptoms of rhinitis medicamentosa during its timeframe, the design cannot rule out rebound congestion with longer-term use beyond the period tested. Those constraints do not diminish the signal in the data; they define how far the result can safely be carried into practice.
ClinicalTrials.gov lists the study under NCT06830109. The main message is narrow but useful: in adults with chronic nasal obstruction who have already failed topical steroids, oxymetazoline/budesonide produced a much higher response rate than budesonide alone, and short-term use did not trigger rebound in the observed cohort.